Fredun Pharmaceuticals Limited (BOM:539730)

Market Cap	7.10B
Revenue (ttm)	5.31B
Net Income (ttm)	275.34M
Shares Out	4.72M
EPS (ttm)	59.30
PE Ratio	25.36
Forward PE	n/a
Dividend	0.70 (0.05%)
Ex-Dividend Date	Sep 23, 2025

Volume	13,964
Average Volume	15,330
Open	1,504.00
Previous Close	1,504.85
Day's Range	1,432.00 - 1,523.90
52-Week Range	635.05 - 1,999.00
Beta	0.64
RSI	43.97
Earnings Date	Nov 8, 2025

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial...

• Industry: Pharmaceutical Preparations
• Founded: 1987
• Employees: 261
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 539730

Financial Performance

In 2024, Fredun Pharmaceuticals's revenue was 4.54 billion, an increase of 30.35% compared to the previous year's 3.48 billion. Earnings were 197.39 million, an increase of 26.34%.